On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi-Center Phase-III Randomized Clinical Trials
In brief
Hierarchical composite endpoints spot treatment benefit more often than standard measures in pediatric supportive care trials
Post-hoc analysis of two Children's Oncology Group phase-III studies showed that using hierarchical composite endpoints increased sensitivity to detect therapeutic advantage and helped reconcile benefits with harms. The approach may clarify complex supportive-care outcomes, but its prospective value needs validation in future trials.
- Journal
- Pediatric blood & cancer (Q1)
- Published
- 25 July 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Willem H Collier, Mark Zobeck, Adam J Esbenshade, Christopher C Dvorak, Lillian Sung, David Freyer, et al.
- PMID
- 42499270
- DOI
- 10.1002/1545-5017.70593
Why clinicians should know about it
- Picked for Hematology (paper of the day, 26 July 2026).
- Picked for Oncology and Radiation Oncology (paper of the day, 26 July 2026): Hierarchical composite endpoints in pediatric cancer supportive care
- Picked for Pediatrics and Child Health (paper of the day, 26 July 2026): Ranked by evidence level and journal quartile
Abstract
Pediatric supportive care clinical trials often involve multiple clinically important outcomes, complicating trial interpretation. Hierarchical composite endpoints (HCEs) provide a framework to integrate key outcomes according to clinical importance. We performed post hoc analyses using HCE in two randomized trials conducted by the Children's Oncology Group. We found that HCE can be more sensitive overall endpoints for detecting treatment benefit as well as found that HCE can support harmonized trial conclusions in the presence of intervention benefits and harms. These analyses illustrate the potential of HCE to improve the interpretability of complex pediatric supportive care trials and support consideration of their prospective use.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.